The new entity – SMS-Oncology GmbH – will be led by Raymond Hoffmans, who said, “Management team chose Frankfurt because of its central location in Germany and a good infrastructure,” including an international airport, train, and highway systems.
“In addition, there is a strong ecosystem of life science companies in Frankfurt and the surrounding area,” Hoffmans told us.
The company is already performing studies at sites in Germany, so opening an office in this location “was the next logical step for company’s growth and expansion plans,” he said.
The contract research organization (CRO), dedicated to oncology, operates in more than 20 countries, and has a local presence in the Nordics and Spain, in addition to the new Germany-based office.
Hoffmans, managing director of SMS-Oncology GmbH, has been the chief business development offices at SMS-Oncology since 2014. He received his PhD from the University of Zurich and joined the Dana Farber Cancer Institute in Boston, MA in the US as a postdoctoral research fellow.